Mylan announced it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) of Tolterodine Tartrate Extended-Release (ER) Capsules, the generic version of Pfizer’s Detrol LA.
Tolterodine tartrate is a muscarinic antagonist indicated for treatment of overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.
These agents lower intravesicular pressure, increase capacity, and reduce the frequency of bladder contractions. They block the parasympathetic nerves which control bladder voiding or exert a direct antispasmodic effect on the detrusor muscle.
Tolterodine Tartrate Extended-Release Capsules are available in 2mg and 4mg dosage strengths.
For more information call (800) RX-MYLAN or visit Mylan.com.